Organisation paid for research Program year 2025 Source: CMS Open Payments

UC Healthcare System

Neither a doctor nor a teaching hospital

Research payments

$7,445,406

1,166 payments

Through program year 2025, UC Healthcare System is reported as receiving $7,445,406 in research payments, across 1,166 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$671,122	117
2024	Research	$815,467	112
2023	Research	$800,114	158
2022	Research	$1,130,563	226
2021	Research	$1,375,079	186
2020	Research	$1,507,753	235
2019	Research	$1,145,308	132

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $1,625,053 120 payments
AstraZeneca Pharmaceuticals LP $1,013,953 17 payments
AbbVie, Inc. $919,389 237 payments
Alkermes, Inc. $889,701 260 payments
Genzyme Corporation $510,415 31 payments
Alexion Pharmaceuticals, Inc. $427,408 16 payments
Boston Scientific Corporation $178,011 30 payments
Sebela Pharmaceuticals Inc. $171,674 26 payments
Amneal Pharmaceuticals LLC $146,673 24 payments
Sage Therapeutics, Inc. $124,129 28 payments

Studies the money was for Research payments · program years 2019–2025

Ensemble $510,407 33 payments
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma $475,482 6 payments
Immunotherapy for HCC in Patients with Cirrhosis/Portal Hypertension Listed for a Liver Transplant $341,239 1 payment
Ocarina I $326,046 11 payments
A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease $292,298 19 payments
A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) $247,290 4 payments
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) $230,560 92 payments
Primary Ms $224,290 26 payments
A Phase 1, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OLZ/SAM in Pediatric Subjects (10-12 Years Old) With Bipolar I Disorder $186,360 43 payments
M14-675 $182,549 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.